Survival of multiple myeloma (MM) has significantly improved over the past decade;
however, a composed group of patients (15% to 20%), named high-risk (HR) MM, still …

Background On the basis of the DREAMM‐2 study (ClinicalTrials. gov identifier
NCT03525678), single‐agent belantamab mafodotin (belamaf) was approved for patients …

Background Despite major therapeutic advances, the rational choice of the most appropriate
first-line regimen in newly diagnosed transplant-ineligible multiple myeloma (TIE-MM) is …

Ixazomib (IXA) is an oral proteasome inhibitor (PI) used in combination with lenalidomide
and dexamethasone (IXA-Rd) for patients with relapsed and/or refractory multiple myeloma …

Multiple myeloma (MM) is a complex hematological malignancy. Advances in therapy over
the last decade have resulted in significant improvement in overall survival for patients with …

Background Multiple myeloma (MM) is the second most common refractory hematologic
cancer. Searching for new targets and prognostic markers for MM is significant. Methods …

Patients with multiple myeloma (MM) experience disabling symptoms that are difficult to
manage and may persist after induction therapy. Monitoring disease-related and induction …

Abstract Background Long noncoding RNA PCAT1 (lnc‐PCAT1) involves in the proliferation
and drug sensitivity of multiple myeloma (MM), while its prognostic role in MM patients is still …

Aim: Obtain clinical consensus on factors impacting first-line prescribing for transplant-
ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). Materials & …

Introduction Ixazomib, lenalidomide, and dexamethasone (IRd) have been approved for the
treatment of relapsed/refractory multiple myeloma (RRMM) based on the results of the …